Crispr Therapeutics (NASDAQ:CRSP)‘s stock had its “buy” rating reiterated by stock analysts at Piper Jaffray Companies in a research note issued on Tuesday, November 26th, TipRanks reports. They currently have a $104.00 price objective on the stock. Piper Jaffray Companies’ price target would indicate a potential upside of 59.12% from the company’s previous close. Piper Jaffray Companies also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($1.20) EPS, Q2 2020 earnings at ($1.30) EPS, Q3 2020 earnings at ($1.39) EPS, Q4 2020 earnings at ($1.49) EPS, FY2020 earnings at ($5.38) EPS, Q1 2021 earnings at ($1.65) EPS, Q2 2021 earnings at ($1.81) EPS, Q3 2021 earnings at ($1.88) EPS and FY2021 earnings at ($7.38) EPS.
Several other research analysts have also commented on CRSP. BTIG Research boosted their price target on Crispr Therapeutics from $51.00 to $59.00 and gave the stock a “positive” rating in a research report on Tuesday, July 30th. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC restated a “buy” rating and set a $62.00 target price on shares of Crispr Therapeutics in a research note on Wednesday, July 31st. Barclays boosted their price target on Crispr Therapeutics from $59.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Finally, Oppenheimer boosted their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, November 25th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $69.54.
Shares of Crispr Therapeutics stock opened at $65.36 on Tuesday. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $58.93 and a 200-day moving average price of $48.44. Crispr Therapeutics has a one year low of $22.22 and a one year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Sell-side analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $390,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BSW Wealth Partners purchased a new position in shares of Crispr Therapeutics during the second quarter worth about $39,000. Balyasny Asset Management LLC purchased a new stake in Crispr Therapeutics in the 2nd quarter valued at approximately $5,165,000. BNP Paribas Arbitrage SA acquired a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at approximately $41,000. Bank of New York Mellon Corp lifted its position in shares of Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the period. Finally, ARK Investment Management LLC lifted its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the period. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Total Return
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.